Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Fundación GECP
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04223596CT.gov Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients | — | Active Not Recruiting | — | — | — |
NCT04227028CT.gov Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | — | Active Not Recruiting | — | — | — |
NCT04005144CT.gov Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03737994CT.gov Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03707938CT.gov Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02737501CT.gov ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | — | Completed | — | — | — |
NCT02784158CT.gov An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brigatinib (this asset) | Fundación GECP | P3 | B · 57 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Brigatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P3 | B · 63 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 60 |
| Hepatocellular Carcinoma | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brigatinib in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brigatinib-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →